17 results match your criteria: "Lilly Corporate Center DC[Affiliation]"
J Patient Rep Outcomes
December 2024
Eli Lilly and Company, Lilly Corporate Center DC 1730, Indianapolis, IN, 46285, USA.
Background: This psychometric analysis generated evidence to support the use of the Functional Assessment of Cancer Therapy item GP5 (GP5) as a measure of tolerability and confirms the appropriateness of categorizing "high side-effect burden" using a rating of 3 or 4 (score ranges 0-4) in patients with advanced/metastatic RET-mutant medullary thyroid cancer (MTC).
Methodology: Blinded, pooled interim data from the safety population (n=290) enrolled in the phase 3 LIBRETTO-531 trial (NCT04211337) were used. Intraclass correlation coefficients (ICC) were calculated for test-retest reliability using data from cycles 1-2 post-baseline.
Cell Metab
April 2023
Programs in Metabolism and Medical & Population Genetics, The Broad Institute of MIT and Harvard, Cambridge, MA 02132, USA; Department of Pediatrics, Boston Children's Hospital, Boston, MA 02115, USA; Department of Pediatrics, Harvard Medical School, Boston, MA 02115, USA. Electronic address:
Associations between human genetic variation and clinical phenotypes have become a foundation of biomedical research. Most repositories of these data seek to be disease-agnostic and therefore lack disease-focused views. The Type 2 Diabetes Knowledge Portal (T2DKP) is a public resource of genetic datasets and genomic annotations dedicated to type 2 diabetes (T2D) and related traits.
View Article and Find Full Text PDFJ Prev Alzheimers Dis
November 2021
John R. Sims, Eli Lilly and Company, Lilly Corporate Center DC 1532, Indianapolis, IN, 46285, Telephone: 317-655-2206, e-mail:
J Bone Miner Metab
November 2016
inVentiv Health Clinical, 504 Carnegie Center, Princeton, NJ, 08540, USA.
A large medical and pharmacy claims database was used to evaluate outcomes in daily teriparatide (D-TPD) patients in Japan. 445 patients were identified (April 2008-July 2013) with 6+ months' pre- and 18+ months' post-index observation. D-TPD 20 µg subcutaneous injection is indicated for individuals at high risk of fracture.
View Article and Find Full Text PDFNature
January 2014
deCODE genetics/Amgen, Sturlugata 8, IS-101 Reykjavík, Iceland.
In a small fraction of patients with schizophrenia or autism, alleles of copy-number variants (CNVs) in their genomes are probably the strongest factors contributing to the pathogenesis of the disease. These CNVs may provide an entry point for investigations into the mechanisms of brain function and dysfunction alike. They are not fully penetrant and offer an opportunity to study their effects separate from that of manifest disease.
View Article and Find Full Text PDFJ Diabetes Sci Technol
July 2013
Eli Lilly and Company, Lilly Corporate Center DC, Indianapolis, IN 46285, USA.
Pen injectors for the administration of insulin have been available since the 1980s. The first insulin pen, NovoPen®, was introduced by Novo in 1985 (http://www.novonordisk.
View Article and Find Full Text PDFJ Clin Pharmacol
August 2010
Discovery and Development Statistics, Eli Lilly and Company, Lilly Corporate Center DC 2026, Indianapolis, IN 46285, USA.
The advent of high-throughput technologies has proven valuable in the assessment of genetic differences and their effects on drug activation, metabolism, disposition, and transport. However, most studies to date have focused on a small number of genes or few alleles, some of which are rare and therefore observed infrequently or lacked rigorous ethnic characterization, thus reducing the ability to extrapolate within and among populations. In this study, the authors comprehensively assessed the allele frequencies of 165 variants comprising 27 drug-metabolizing enzyme and transporter (DMET) genes from 2188 participants across 3 major ethnic populations: Caucasians, Africans, and East Asians.
View Article and Find Full Text PDFJ Clin Pharmacol
December 2009
Eli Lilly and Company, Lilly Corporate Center DC 2128, Indianapolis, IN 46285, USA.
This study evaluated the pharmacodynamics and pharmacokinetics of once-daily dosing of warfarin at steady state when taken concomitantly with once-daily doses of duloxetine. Healthy subjects with a stable international normalized ratio (INR) of 1.5 to 2.
View Article and Find Full Text PDFJ Clin Pharmacol
April 2008
Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center DC 0724, Indianapolis, IN 46285, USA.
Prasugrel and clopidogrel, thienopyridine prodrugs, are each metabolized to an active metabolite that inhibits the platelet P2Y(12) ADP receptor. In this open-label, 4-period crossover study, the effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel were assessed in healthy subjects given single doses of prasugrel 60 mg and clopidogrel 300 mg with and without concurrent lansoprazole 30 mg qd. C(max) and AUC(0-tlast) of prasugrel's active metabolite, R-138727, and clopidogrel's inactive carboxylic acid metabolite, SR26334, were assessed.
View Article and Find Full Text PDFBiom J
February 2008
Exploratory Program Medical Statistics, Eli Lilly and Company, Lilly Corporate Center DC 0710, Indianapolis, IN 46285, USA.
We consider a Bayesian analysis for modeling a binary response that is subject to misclassification. Additionally, an explanatory variable is assumed to be unobservable, but measurements are available on its surrogate. A binary regression model is developed to incorporate the measurement error in the covariate as well as the misclassification in the response.
View Article and Find Full Text PDFJ Clin Pharmacol
September 2007
Eli Lilly and Company, Lilly Corporate Center DC 0734, Indianapolis, IN 46285, USA.
The safety, tolerability, and pharmacokinetics of orally administered enzastaurin were evaluated in 2 placebo-controlled, dose escalation studies in healthy subjects. In the first human dose study, single doses (2-400 mg) were evaluated, with 22 subjects receiving enzastaurin. The mean half-lives of enzastaurin and its metabolites ranged from approximately 12 to 40 hours.
View Article and Find Full Text PDFDiabetes Care
January 2007
Eli Lilly, Lilly Corporate Center DC 2138, Indianapolis, IN 46285, USA.
Objective: We examined changes in metabolic parameters in clinical trials of duloxetine for diabetic peripheral neuropathic pain (DPNP).
Research Design And Methods: Data were pooled from three similarly designed clinical trials. Adults with diabetes and DPNP (n = 1,024) were randomized to 60 mg duloxetine q.
Nat Rev Drug Discov
February 2005
Eli Lilly and Company, Neuroscience Division, Lilly Corporate Center DC 0510, Indianapolis, Indiana 46285, USA.
Anxiety and stress disorders are the most commonly occurring of all mental illnesses, and current treatments are less than satisfactory. So, the discovery of novel approaches to treat anxiety disorders remains an important area of neuroscience research. Glutamate is the major excitatory neurotransmitter in the mammalian central nervous system, and G-protein-coupled metabotropic glutamate (mGlu) receptors function to regulate excitability via pre- and postsynaptic mechanisms.
View Article and Find Full Text PDFPsychiatry Res
July 2003
Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center DC 6324, 46285, Indianapolis, IN, USA.
Prolongation of the QTc interval has been reported during treatment with oral antipsychotic agents and may be more pronounced during parenteral administration. Pooled QTc interval data from acutely agitated patients across four double-blind trials were compared. Databases included: placebo-controlled [two schizophrenia, one bipolar mania trials (n=565)]; haloperidol-controlled [two schizophrenia trials (n=482)]; geriatric placebo-controlled [1 dementia trial (n=204)].
View Article and Find Full Text PDFJ Clin Psychiatry
February 2003
Eli Lilly and Company, Lilly Corporate Center DC-6026, Indianapolis, IN 46285, USA.
Atomoxetine is a selective norepinephrine reuptake inhibitor that is being developed for the treatment of attention-deficit/hyperactivity disorder (ADHD). Atomoxetine will be the first nonstimulant medication approved by the U.S.
View Article and Find Full Text PDFClin Cancer Res
August 2001
Cancer Research Division, Lilly Research Labs, Eli Lilly and Company, Lilly Corporate Center DC 0546, Indianapolis, IN 46285, USA.
Purpose: The AKT/PKB kinase controls many of the intracellular processes that are dysregulated in human cancer, including the suppression of apoptosis and anoikis and the induction of cell cycle progression. Three isoforms of AKT have been identified: AKT-1, -2, and -3. Selective up-regulation of AKT-3 RNA expression has been reported in hormone-independent breast and prostate cancer cell lines suggesting that AKT-3 expression may be increased with breast or prostate tumor progression.
View Article and Find Full Text PDF